Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 5:04 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 1,484 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Standard Scheduling Clear all

Conditions: Center-involved Diabetic Macular Edema (CI-DME)
Interventions: Diabetes Visual Function Study (DiVFuSS) softgels, canola oil placebo softgels, 2 per day; Dietary Supplement · Other
Lead sponsor: ZeaVision, LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 2
States / cities: Olympia, Washington • Tacoma, Washington

Conditions: Oral Cancer Directed Therapy, Breast Cancer, Gastrointestinal Cancer, Oral Chemotherapy
Interventions: Active Care Team Alert, Passive Care Team Alert; Other
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer, Axillary Lymph Node Dissection
Interventions: isosulfan blue dye; Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 21 Years and older · Female only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Moderate to Severe Psoriatic Arthritis
Interventions: DDY391, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 3
States / cities: Memphis, Tennessee • Colleyville, Texas • San Antonio, Texas

Conditions: Smoking Cessation
Interventions: Questionnaire, In-Depth Interviews, Breath Test, Nicotine Patches, Advice plus Phone Counseling, Advice plus Counseling Sessions, Self Assessment Questionnaires; Behavioral · Other · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 25 Years to 65 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Widspread Chronic Pain, Fibromyalgia
Interventions: Vagal nerve stimulation through deep exhalation exercise, Vagal nerve stimulation through ear electrical stimulation, No intervention (observational study); Other
Lead sponsor: University of North Georgia; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Dahlonega, Georgia

Conditions: Brain Cancer
Interventions: erlotinib, Cytoreductive Surgery; Drug · Procedure
Lead sponsor: Andrew B Lassman, MD; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 4
States / cities: Basking Ridge, New Jersey • Commack, New York • New York, New York

Conditions: Infertility, Female
Interventions: Abdominal ultrasound measurement of the endometrial lining; Diagnostic Test
Lead sponsor: Boston IVF; Other
Eligibility: 18 Years to 44 Years · Female only
Enrollment: 187 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Acute Myeloid Leukemia With 11q23-abnormality in Relapse
Interventions: Temozolomide, Vorinostat; Drug
Lead sponsor: Steven E. Coutre; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Stanford, California

Conditions: High Grade Myelodysplastic Syndromes
Interventions: Omacetaxine, Azacitidine; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Endometritis, Cesarean Section; Infection, Wound Infection
Interventions: Azithromycin 500 mg, Mefoxin 2g; Drug
Lead sponsor: RWJ Barnabas Health at Jersey City Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Jersey City, New Jersey

Conditions: Neonatal Anemia
Interventions: Epoetin Alpha; Drug
Lead sponsor: University of Iowa; Other
Eligibility: Up to 2 Days
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Myelodysplastic Syndromes
Interventions: FDA-approved drug or combination of drugs, FLAG induction, 7 + 3 induction, Low-dose cytarabine, Supportive care alone, Computational biology simulations software; Drug · Other · Device
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 99 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Glioblastoma, Brain Tumor, GBM
Interventions: Pembrolizumab, Vorinostat, Temozolomide, Radiotherapy; Drug · Radiation
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Cardiomyopathy, Cardiovascular Disease, Heart Disease
Interventions: Respiratory Depression Monitoring with End Tidal Carbon Dioxide Nasal Cannula (ETCO2- NC), Standard Non-invasive Respiratory Depression Monitoring; Device · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Maintenance of Implanted Port Devices
Interventions: Reduced IPD Flush Schedule, Standard IPD Flush Schedule; Device
Lead sponsor: Essentia Health; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 17
States / cities: Albert Lea, Minnesota • Brainerd, Minnesota • Deer River, Minnesota + 13 more

Conditions: NSCLC, Breast Cancer
Interventions: Poziotinib; Drug
Lead sponsor: Spectrum Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 5
States / cities: Long Beach, California • Hattiesburg, Mississippi • New York, New York + 2 more

Conditions: Morbid Obesity
Interventions: Very low calorie diet; Dietary Supplement
Lead sponsor: Christiana Care Health Services; Other
Eligibility: 18 Years to 65 Years
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Colonoscopy
Interventions: Golytely (polyethylene glycol), MiraLax (polyethylene glycol 3350); Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 50 Years to 90 Years
Enrollment: 432 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Benign Prostatic Hyperplasia (BPH)
Interventions: Treatment Device: The ALPFA Medical (ALPFA) GRAIL™ Pulsed Field Ablation (PFA) System, Control Device: Sham flexible cystoscopy; Device
Lead sponsor: ALPFA Medical; Industry
Eligibility: 45 Years and older · Male only
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Germantown, Tennessee

Conditions: Breast Cancer
Interventions: Bevacizumab, Standard adjuvant chemotherapy; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 2,591 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 44
States / cities: Huntsville, Alabama • Mobile, Alabama • Fayetteville, Arkansas + 40 more

Conditions: Diabetes
Interventions: Capillary blood glucose blood draw; Diagnostic Test
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Timeline: 2021
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Sepsis, Burn Injury, Wound Healing, Critical Illness, Multiple Organ Dysfunction Syndrome
Interventions: Observational Cohort (No Intervention); Other
Lead sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine; Other
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Tampa, Florida • Atlanta, Georgia • Houston, Texas

Conditions: High-need, High-complexity
Interventions: Primary Hospital Provider Team; Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Madison, Wisconsin

Search by objective public record fields.

Prospective Study of Adjunctive Carotenoids Plus Anti-oxidants in Anti-VEGF Treated Diabetic Macular Edema

EHR-embedded OCDT in Breast or GI Cancer

Upper Extremity Lymphatic Mapping for Breast Cancer Patients

A Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis

Health Literacy and Smoking Cessation in Low-SES Diverse Smokers - Project HALT II

The Effect of Vagus Nerve Stimulation on Pain and Functional Activities in Individuals With Chronic Widespread Pain

EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas

Impact of Endometrial Compaction in Euploid Frozen Embryo Transfers

Temozolomide Plus Vorinostat in Relapse/Refractory Acute Myeloid Leukemia (AML)

Omacetaxine + Azacitidine in Untreated Patients With High Grade MDS

Two-drug Antibiotic Prophylaxis in Scheduled Cesarean Deliveries

Optimized Erythropoietin (EPO) Treatment

iCare 2: Personalized Genomic Mutation Informed Treatment of Patients With Myelodysplastic Syndromes

Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma

Employing End Tidal Capnography in Continuous Flow Ventricular Assist Device Patients

Safety of Extending The Routine Flushing Of Implanted Port Devices From 4 Weeks To 12

A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to Poziotinib

Utilization of Very Low Calorie Diet in Obese General Surgery Patients

A Trial Comparing Bowel Preparation and Patient Tolerability of Miralax Versus Golytely

To Establish the Safety and Effectiveness of the ALPFA GRAIL PFA System for Treating Symptomatic Benign Prostate Hyperplasia (BPH) Also Known as an Enlarged Prostate.

BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer

Glycemic Control Based on Serum Fructosamine Concentration vs. hemoglobinA1c (HbA1c) in Diabetic Patients

Surgical Critical Care Initiative (SC2i) Tissue and Data Acquisition Protocol (TDAP) in Burn Patients Improving the Robustness and Generalizability of Post-burn Sepsis Prediction With the Post-Burn Sepsis Digital Twin. Group 1

Implementation of a Primary Hospital Provider (PHP) Team